Genprex, Inc. Common Stock
GNPXGenprex, Inc. is a gene therapy company focused on developing immuno-oncology treatments for cancer. The company's lead product candidate is Oncoprex, an immunotherapy designed to activate the immune system to target tumors. Founded with the goal of advancing genetic medicine, Genprex develops innovative therapies aimed at improving outcomes for cancer patients.
Company News
Congressman Tim Moore (R-N.C.), who achieved a 52% return on stock trades in 2025 outperforming the S&P 500, continues buying small-cap stocks in 2026. His latest purchases include additional shares of Genprex, a gene therapy company with a $5.2 million market cap that he also bought in 2025, and Simply Good Foods, which is down 53% over the past...
Genprex's research collaborators will present positive preclinical data on the use of Reqorsa® Gene Therapy for treating Ras inhibitor resistant lung cancer, mesothelioma, and glioblastoma at the 2024 EORTC-NCI-AACR Symposium.
Genprex (GNPX) gains 9.5% after expanding clinical study sites in the United States for the early to mid-stage study of lead candidate, Reqorsa, to treat lung cancer patients.
Shares of United Natural Foods, Inc. (NYSE: UNFI) fell sharply during Wednesday’s session following second-quarter results. United Natural Foods posted adjusted earnings of 7 cents per share, compared to market estimates for a loss of 1 cent per share. The company’s quarterly sales came in at $7.78 billion, versus expectations of $7.87 billi...
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling around 1.5% on Wednesday. The Dow traded down 0.21% to 38,384.83 while the NASDAQ fell 1.53% to 15,272.34. The S&P 500 also fell, dropping, 1.02% to 4,874.63. Check This Out: Jim Cramer Says It's 'Still Not Too Late' To Buy This Energy Stock  Leading and Lagg...
